Abbott's first quarter diagnostic revenues decreased around 2 percent year over year, although its molecular diagnostic sales inched up a fraction of a percent.
The deal includes PersonalizeDx's portfolio of proprietary fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, as well as a CLIA lab.
Many of the meeting's proteomics presentations concerned not so much mass spec analysis itself as the refinement of processes and workflows leading up to it.
The RT-PCR/ESI-MS system showed similar sensitivity and specificity to tests from Cepheid and Hologic.
Its MDx sales were flat for the second Q4 in a row, while Abbott's overall revenues were hit by foreign exchange.
Abbott is looking to develop molecular and companion diagnostic assays based on mutations in the FGFR3 gene, which are found in many early stage bladder cancers.
An RT-qPCR-based assay of antigen-stimulated blood is a possible next-gen approach for latent TB detection, a Cepheid executive noted in an accompanying commentary.
Trends included expanding test menus and a possible tipping point for point-of-care.
The researchers are also developing the method in tandem with a more extensive pathogen profiling diagnostic platform from Swedish startup Q-linea.
The platform, called Iridica, uses a combination of PCR and electrospray ionization mass spectrometry to amplify and detect a wide variety of pathogens.
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
In Science this week: the synthetic genetic system hachimoji, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.